HLA Typing for Transplant Market Size, Share & Industry Analysis, By Offering (Instruments & Systems, Reagents & Consumables, Software & Bioinformatics, HLA Typing Services), By Technology (Next-Generation Sequencing (NGS), Sanger Sequence-Based Typing (SBT), PCR–Sequence-Specific Oligonucleotide (PCR-SSO), PCR–Sequence-Specific Primer (PCR-SSP), Real-Time PCR / qPCR-Based HLA Typing), By Transplant Type (Solid Organ Transplantation, Hematopoietic Stem Cell Transplantation), By End User (Hospitals & Transplant Centers, Independent & Reference HLA Laboratories), & Regional Forecast, 2026-2034

The global HLA typing for transplant market size was valued at USD 725.7 million in 2025. The market is projected to grow from USD 783.1 million in 2026 to USD 1,471.0 million by 2034, exhibiting a CAGR of 8.2% during the forecast period.

The global market comprises molecular assays, sequencing platforms, reagents, software, bioinformatics tools, and laboratory services used to characterize human leukocyte antigen alleles and assess donor-recipient compatibility before solid-organ and hematopoietic stem cell transplantation. Accurate HLA typing supports donor selection, reduces immunologic incompatibility risk, and helps clinicians manage graft rejection and graft-versus-host disease risk. The market growth is attributed to rising transplant volumes, expansion of donor registries, increasing adoption of high-resolution molecular typing, growing use of next-generation sequencing, and continued automation of high-throughput histocompatibility laboratories.

• For instance, according to data published by the Global Observatory on Donation and Transplantation (GODT), the solid-organ transplant activity reached a record 173,727 procedures in 2024, supporting sustained demand for donor-recipient compatibility testing.

Furthermore, Thermo Fisher Scientific Inc., Eurobio Scientific, Werfen, HistoGenetics LLC, and DKMS Life Science Lab GmbH are among the prominent participants in the HLA typing ecosystem, supported by sequencing workflows, molecular assays, bioinformatics capabilities, high-throughput laboratory operations, and transplant-focused testing services.

HLA TYPING FOR TRANSPLANT MARKET TRENDS

Shift Toward High-Resolution NGS and Integrated Bioinformatics is Transforming Histocompatibility Testing

Transplant laboratories are increasingly adopting higher-resolution HLA typing workflows that combine next-generation sequencing with specialized bioinformatics for allele assignment, phasing, quality control, and interpretation. Compared with legacy lower-resolution methods, NGS can provide broader locus coverage and reduce ambiguity, supporting more refined donor selection for both solid-organ and stem-cell transplantation. The market is also moving toward faster library preparation, multiplex amplification, long-read sequencing, workflow automation, and integrated sample-to-report software. These developments are particularly important for high-throughput donor registries and reference laboratories that must process large sample volumes while maintaining accuracy and turnaround time.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Transplant Volumes and Need for Accurate Donor-recipient Matching to Drive Market Growth

Increasing numbers of kidney, liver, heart, lung, and hematopoietic stem cell transplants are strengthening demand for reliable histocompatibility testing. HLA compatibility remains an important component of donor selection and transplant risk assessment, particularly where high-resolution matching can help differentiate potential donors. Growth of deceased- and living-donor programs, stem-cell donor registries, and transplant-center capacity is increasing the number of samples requiring HLA characterization. At the same time, laboratories are adopting molecular methods capable of delivering higher resolution, greater locus coverage, and improved reproducibility, thereby supporting recurring demand for reagents, sequencing workflows, software, and specialized services.

MARKET RESTRAINTS

High Cost of Advanced Molecular Typing and Uneven Laboratory Infrastructure May Restrict Adoption

Advanced HLA typing workflows require sequencing platforms, validated assays, trained molecular laboratory personnel, bioinformatics infrastructure, quality assurance, and ongoing reagent expenditure. These requirements can create adoption barriers for smaller laboratories and healthcare systems with limited testing volumes. Migration from established PCR- or Sanger-based workflows to NGS may also involve validation costs, workflow redesign, data-management requirements, and integration with laboratory information systems. Uneven reimbursement and differences in transplant-testing infrastructure across countries may further limit uniform adoption of high-resolution technologies.

MARKET OPPORTUNITIES

Expansion of Donor Registries, Long-read Sequencing, and Automated HLA Interpretation to Create Significant Opportunities

Growth of stem-cell donor registries and transplant programs creates opportunities for high-throughput HLA typing platforms, automated sample preparation, and scalable bioinformatics. Long-read sequencing can improve phasing and full-gene characterization, while software-based interpretation can help laboratories manage increasingly complex allele data. Vendors that combine reagents, sequencing compatibility, automated analysis, database connectivity, and reporting can address the growing need for integrated workflows. Emerging transplant programs in Asia Pacific, Latin America, and the Middle East also provide opportunities for laboratory capacity expansion and adoption of standardized molecular typing.

MARKET CHALLENGES

Managing HLA Complexity, Data Interpretation, and Standardization Across Laboratories Remains Challenging

The HLA region is highly polymorphic, making accurate allele assignment, phasing, ambiguity resolution, and quality control technically demanding. Laboratories must maintain validated reference databases and analytical pipelines while accommodating new alleles and evolving nomenclature. Differences in platforms, assay designs, software algorithms, accreditation requirements, and reporting practices can complicate cross-laboratory standardization. High-resolution sequencing also generates larger datasets, increasing requirements for bioinformatics expertise, data storage, cybersecurity, and integration with transplant information systems.

Segmentation Analysis

By Offering

Recurring Testing Requirements Boosted Reagents & Consumables Segment

Based on offering, the market is divided into instruments & systems, reagents & consumables, software & bioinformatics, and HLA typing services.

The reagents & consumables segment accounted for the largest global HLA typing for transplant market share in 2025. The segment growth is attributed to recurring demand for amplification reagents, sequencing kits, primers, probes, library-preparation materials, controls, and other assay consumables required for every HLA typing workflow. Unlike capital instruments, consumables generate repeat purchases as transplant centers, donor registries, and reference laboratories process new donor and recipient samples. Increasing adoption of multi-locus and high-resolution molecular assays further raises reagent consumption per test and supports the segment's dominant market position.

The software & bioinformatics segment is anticipated to rise with a CAGR of 10.9% over the forecast period.  

To know how our report can help streamline your business, Speak to Analyst

By Technology

High-Resolution Allele Characterization Propelled Next-Generation Sequencing (NGS) Segmental Dominance

Based on technology, the market is segmented into next-generation sequencing (NGS), Sanger sequence-based typing (SBT), PCR–sequence-specific oligonucleotide (PCR-SSO), PCR–sequence-specific primer (PCR-SSP), real-time PCR / qPCR-based HLA typing, and others.

The next-generation sequencing (NGS) segment held the highest share of the global market in 2025. The segment growth is attributed to increasing demand for high-resolution HLA typing, broader locus coverage, improved allele discrimination, and reduced ambiguity in donor-recipient matching. NGS workflows can simultaneously analyze multiple HLA loci and support scalable processing of transplant and donor-registry samples. Continued improvements in sequencing throughput, multiplexing, library preparation, and HLA-specific analysis software are further strengthening adoption in high-volume histocompatibility and transplant laboratories.

The real-time PCR / qPCR-based HLA typing segment is anticipated to rise with a considerable CAGR of 8.8% over the forecast period.  

By Transplant Type

Large Procedure Base and Routine Compatibility Testing Led to Dominance of Solid Organ Transplantation Segment

Based on transplant type, the market is segmented into solid organ transplantation, hematopoietic stem cell transplantation, and others.

The solid organ transplantation segment accounted for the largest share of the global market in 2025. The segment growth is attributed to the large volume of kidney, liver, heart, lung, and other solid-organ transplant procedures, continued expansion of transplant programs, and the clinical importance of immunologic compatibility assessment. Kidney transplantation represents the largest solid-organ transplant category globally, creating substantial recurring demand for donor and recipient HLA characterization. Growth in living-donor programs and deceased-donor transplantation further supports testing volumes across transplant centers and histocompatibility laboratories.

The hematopoietic stem cell transplantation segment is anticipated to rise with a CAGR of 8.5% over the forecast period.

By End User

Concentration of Transplant Procedures and Clinical Decision-making Boosted Hospitals & Transplant Centers Segmental Dominance

Based on end user, the market is segmented into hospitals & transplant centers, independent & reference HLA laboratories, and others.

The hospitals & transplant centers segment held a major market share of 59.2% in 2025. The segment growth is attributed to the concentration of solid-organ and stem-cell transplant procedures within specialized centers, the need for pre-transplant donor-recipient compatibility assessment, and close integration between histocompatibility results and clinical decision-making. Major transplant centers maintain dedicated or affiliated laboratories and generate recurring demand for HLA typing across recipient evaluation, donor workup, confirmatory testing, and transplant planning. Their access to advanced molecular diagnostics and multidisciplinary transplant teams further supports the segment's leading position.

The independent & reference HLA laboratories segment is anticipated to rise with a CAGR of 9.0% over the forecast period.

HLA Typing for Transplant Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024, valued at USD 265.5 million, and also maintained the leading share in 2025, with USD 282.9 million. The region benefits from substantial kidney and hematopoietic stem cell transplant activity, established histocompatibility laboratory networks, and continued adoption of high-resolution HLA typing.

U.S. HLA Typing for Transplant Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 274.0 million in 2026, accounting for roughly 35.0% of global sales.

Europe

Europe is projected to record a growth rate of 11.0% in the coming years and reach a valuation of USD 232.0 million by 2026. Europe is projected to witness strong growth during the forecast period due to established organ-donation systems, large stem-cell donor registries, strong immunogenetics laboratory infrastructure, and continued adoption of high-resolution HLA typing.

U.K. HLA Typing for Transplant Market

The U.K. market is estimated at around USD 37.3 million in 2026, representing roughly 4.8% of global revenues.

Germany HLA Typing for Transplant Market

Germany’s market is projected to reach approximately USD 43.1 million in 2026, equivalent to around 5.5% of global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 186.4 million in 2026 and secure a significant position in the market. The regional market is growing due to rising organ and stem-cell transplant volumes, increasing prevalence of chronic diseases leading to organ failure, and expansion of transplant centers and donor registries.

Japan HLA Typing for Transplant Market

The Japanese market is estimated at around USD 30.8 million in 2026, accounting for roughly 3.9% of global revenues.

China HLA Typing for Transplant Market

China’s market is projected to be one of the largest globally, with 2026 revenues estimated at around USD 61.5 million, representing roughly 7.9% of global sales.

India HLA Typing for Transplant Market

The Indian market is estimated at around USD 26.9 million in 2026, accounting for roughly 3.4% of global revenues.

Latin America and Middle East & Africa

Latin America and Middle East & Africa regions are expected to witness moderate growth in this market during the forecast period. Latin America’s market is set to reach a valuation of USD 37.7 million in 2026. The market is driven by expanding transplant programs, improving healthcare infrastructure, and growing donor registries, while the Middle East & Africa market is supported by rising investment in transplant centers, increasing organ donation initiatives, and gradual adoption of advanced molecular HLA typing technologies.

GCC HLA Typing for Transplant Market

The GCC market is set to reach a value of USD 13.0 million in 2026.

South Africa HLA Typing for Transplant Market

South Africa’s market is projected to reach around USD 4.7 million in 2026, representing roughly 0.6% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Portfolio Expansion and High-resolution Molecular Typing Capabilities Strengthen Market Positioning of Leading Players

The global HLA typing for transplant market has a competitive structure comprising molecular diagnostic manufacturers, sequencing solution providers, specialist immunogenetics companies, and large reference laboratories. Prominent participants include Thermo Fisher Scientific Inc., Eurobio Scientific, Werfen, HistoGenetics LLC, and DKMS Life Science Lab GmbH. These organizations maintain market positions through broad HLA assay portfolios, sequencing compatibility, bioinformatics capabilities, high-throughput laboratory capacity, established transplant-center relationships, and continued investment in high-resolution typing workflows.

• For instance, in 2026, Werfen introduced NanoTYPE HLA-11 Plus as a CE-IVD full-gene HLA typing kit covering 11 classical HLA genes, supporting the shift toward broader high-resolution sequencing workflows.

Other notable participants include Labcorp, Quest Diagnostics Incorporated, BAG Diagnostics GmbH, TBG Biotechnology Corp., and inno-train Diagnostik GmbH. These companies are expected to prioritize workflow automation, assay expansion, high-resolution sequencing, bioinformatics integration, and partnerships with transplant centers and reference laboratories to strengthen their market presence.

LIST OF KEY HLA TYPING FOR TRANSPLANT COMPANIES PROFILED

• Thermo Fisher Scientific Inc. (U.S.)
• Eurobio Scientific (France)
• Werfen (Spain)
• HistoGenetics LLC (U.S.)
• DKMS Life Science Lab GmbH (Germany)
• Labcorp (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• BAG Diagnostics GmbH (Germany)
• TBG Biotechnology Corp. (Taiwan)
• inno-train Diagnostik GmbH (Germany)

KEY INDUSTRY DEVELOPMENTS

• November 2025: Narayana Health announced plans to organize one of the largest HLA testing camps in Eastern India in Kolkata, in collaboration with DKMS, Thalassemics India, Coal India, and other organizations.
• November 2025: DKMS Life Science Lab highlighted expansion of automation and robotics within its high-throughput HLA typing operations to support large-scale donor typing.
• June 2025: DKMS Life Science Lab participated in the 38th European Immunogenetics and Histocompatibility Conference, which focused on new developments in immunogenetics and clinical transplantation.
• October 2024: CareDx showcased advancements across its AlloSeq NGS-based HLA typing portfolio and introduced enhancements to its QTYPE real-time PCR solution at the 50th Annual Meeting of the American Society for Histocompatibility and Immunogenetics (ASHI).
• January 2023: Metropolis Healthcare launched NextGen HLA Typing, a high-resolution molecular test powered by Next-Generation Sequencing (NGS) for hematopoietic stem cell transplantation (HSCT) and solid-organ transplantation.

REPORT COVERAGE

The global HLA typing for transplant market analysis includes a comprehensive study of the market size & forecast by all the market segments included in the report. It includes details on the market dynamics and market trends expected to drive the market over the forecast period. It provides information on key aspects, including an overview of technological advancements, the regulatory environment, and product launches. Additionally, it details partnerships, mergers & acquisitions, as well as key industry developments and investments by key regions. The global market research report also provides a depth competitive landscape with information on the market share and profiles of key operating players.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom Up Approaches

Approach 1. Country-Level Transplant Activity & HLA Typing Spending Analysis

• Assess solid organ and hematopoietic stem cell transplantation activity across each country in scope.
• Analyze transplant candidates, recipients, potential donors, donor registries, waiting lists, and transplant-center infrastructure.
• Separate HLA typing expenditure from broader transplant diagnostics such as antibody screening, PRA/cPRA testing, crossmatching, chimerism testing, and rejection monitoring.
• Evaluate country-level HLA laboratory availability, reimbursement environment, healthcare spending, molecular-diagnostics maturity, and adoption of high-resolution typing.
• Assess technology penetration across NGS, Sanger SBT, PCR-SSO, PCR-SSP, and real-time PCR/qPCR-based HLA typing.
• Estimate country market values using transplant activity × HLA typing intensity × technology/service mix × country-specific pricing, and aggregate country estimates to regional and global totals.

Approach 2: Bottom-Up HLA Test Volume & Utilization Analysis

• Estimate the addressable population of transplant recipients, transplant candidates, potential related/unrelated donors, registry donors, and confirmatory/repeat testing cases.
• Determine HLA typing intensity across each transplant pathway, including recipient typing, donor typing, confirmatory typing, repeat/reflex testing, and donor-search-related typing.
• Estimate annual HLA typing volumes separately for solid organ transplantation and hematopoietic stem cell transplantation.
• Apply country-specific technology shares across NGS, Sanger SBT, PCR-SSO, PCR-SSP, real-time PCR/qPCR, and other technologies.
• Calculate attributable revenues from reagents & consumables, instruments & systems, software & bioinformatics, and HLA typing services, while adjusting for outsourcing and bundled solutions.
• Calculate market value using HLA test volumes × average revenue per test/service, supplemented by HLA-attributable instrument and software revenues, while preventing double counting.

Approach 3: Credible Secondary Sources & Institutional Data Cross-Check

• Use ASHI, EFI, WMDA, NMDP, EBMT, and national histocompatibility/transplant organizations for HLA typing practices, donor activity, accreditation, and testing standards.
• Use HRSA/OPTN, FDA, European Commission/IVDR, PMDA, NMPA, CDSCO, and TGA for regulatory, transplant, and product-registration requirements.
• Use WHO, Global Observatory on Donation and Transplantation, OECD, Eurostat, World Bank, national transplant registries, and health ministries for transplant and healthcare-system validation.
• Validate organ transplant volumes, HSCT volumes, donor-registry populations, HLA laboratory capacity, technology adoption, and reimbursement conditions.
• Use official company filings, HLA product pages, service portfolios, regulatory approvals, customer information, and press releases for commercial validation.
• Exclude third-party syndicated market-research publishers as primary evidence sources for market size, growth rate, company share, and country-level estimates.

2. Top Down Approaches

Approach 1: Revenues and Market Share of Major Players (2021-2025)

• Collect company-level revenues and operating indicators from annual reports, SEC filings, investor presentations, earnings materials, and acquisition disclosures.
• Map vendors to the finalized Product Type categories and exclude generic enterprise/healthcare cybersecurity revenue.
• Assess customer base, healthcare penetration, protected-device counts, ARR/subscription economics, and geographic presence.
• Estimate in-scope medical-device cybersecurity revenue using product relevance, customer indicators, contracts, and healthcare exposure.
• Calculate indicative company market shares and estimate the residual Others pool.
• Aggregate vendor-level revenues to derive the preliminary supply-side market size.

Approach 2: Triangulation, Validation and Forecast Modeling

• Compare estimates derived from company revenues, country-level transplant/HLA spending, and bottom-up HLA test-volume analysis.
• Investigate and reconcile material differences between supply-side and demand-side estimates.
• Remove overlap with antibody testing, crossmatching, transplant monitoring, and other non-HLA transplant diagnostics, while preventing double counting between products and laboratory services.
• Validate estimates against transplant volumes, donor-registry activity, HLA test intensity, laboratory capacity, technology adoption, assay pricing, and company geographic exposure.
• Develop country, regional, and segment forecasts using transplant-volume growth, donor-registry expansion, NGS penetration, high-resolution typing adoption, laboratory automation, reimbursement, and technology replacement trends.
• Apply conservative, base, and high-growth scenarios and lock the final market size and CAGR after triangulation across all approaches.

3. List of Key Sources

• Annual reports, SEC/regulatory filings, investor presentations, earnings disclosures, acquisition filings, and product-level commercial disclosures
• American Society for Histocompatibility and Immunogenetics (ASHI)
• European Federation for Immunogenetics (EFI)
• World Marrow Donor Association (WMDA)
• NMDP
• European Society for Blood and Marrow Transplantation (EBMT)
• HRSA / Organ Procurement and Transplantation Network (OPTN)
• Scientific Registry of Transplant Recipients (SRTR)
• National organ-transplant and hematopoietic stem-cell transplant registries
• Global Observatory on Donation and Transplantation / WHO
• U.S. FDA
• European Commission / EU IVDR
• PMDA / MHLW
• NMPA
• CDSCO
• TGA
• OECD
• Eurostat
• World Bank
• National health ministries, reimbursement agencies, and statistical organizations
• Company HLA typing product catalogs, technical documents, service portfolios, regulatory approvals, customer cases, and press releases

4. Primary Interviews

Supply Side Interviews: 60%

• Key respondents: LA typing assay and reagent manufacturers, sequencing-based HLA solution providers, transplant-diagnostics companies, molecular-diagnostics manufacturers, HLA software/bioinformatics providers, independent/reference HLA laboratories, commercial HLA typing service providers, product managers, commercial executives, laboratory-science specialists, regulatory-affairs professionals, distributors, and channel partners.
• Validate HLA typing revenues, offering-level revenue mix, assay pricing, reagent consumption, installed-base trends, instrument utilization, test/service volumes, NGS penetration, software contribution, geographic presence, customer penetration, distribution structure, and competitive positioning.
• Demand Side Interviews: 40%
• Key Respondents: Transplant-center laboratory directors, histocompatibility/HLA laboratory professionals, transplant physicians, transplant coordinators, hospital laboratory managers, independent/reference laboratory executives, procurement professionals, donor-registry personnel, organ-transplant program representatives, molecular pathologists, and reimbursement/payer stakeholders.
• Validate HLA test volumes, donor/recipient typing frequency, confirmatory/repeat testing intensity, technology preferences, outsourcing levels, reagent utilization, annual laboratory expenditure, procurement cycles, turnaround-time requirements, reimbursement conditions, and laboratory capacity.